|
|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192990-03
|
$171,681
|
$171,681
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
|
(1) Intestinal Organoid Models for APC LOH
|
1R21CA208638-01
|
$232,195
|
$232,195
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-07
|
$1,275,740
|
$1,275,740
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
1R21CA205636-01
|
$168,563
|
$168,563
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-07
|
$730,767
|
$730,767
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research
|
5P20CA192988-03
|
$184,939
|
$184,939
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy
|
1R01CA208526-01
|
$484,047
|
$484,047
|
CUCINOTTA, FRANCIS
|
UNIVERSITY OF NEVADA LAS VEGAS
|
|
|
(ACN 12011-001-00004) FOR CBRG FOR THE CENTER FOR PROSTATE DISEASE RESEARCH
|
ACN12011001
|
$459,666
|
$459,666
|
UNKNOWN, UNKNOWN
|
UNIFORM THE SERVICES UNIVERSITY OF THE HEALTH
|
|
|
(NCI) Developing an Intermediate Energy Linac for Robotic Radiotherapy
|
3R43CA183390-01A1S1
|
$40,000
|
$40,000
|
BOUCHER, SALIME
|
RADIABEAM TECHNOLOGIES, LLC
|
|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto
|
5R01CA190121-03
|
$332,000
|
$332,000
|
VERHAAK, ROELAND
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors
|
1R21CA208723-01
|
$212,824
|
$212,824
|
BETTEGOWDA, CHETAN
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
1R01CA208535-01
|
$536,390
|
$536,390
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
1R01CA206025-01
|
$655,037
|
$655,037
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
1R01CA205258-01
|
$464,261
|
$464,261
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
|
(PQ1) Epigenetic effects of the premalignant field
|
1R01CA208620-01
|
$357,464
|
$357,464
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
1R01CA205954-01
|
$438,499
|
$438,499
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
1R01CA206026-01
|
$356,850
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer
|
1R01CA205608-01A1
|
$360,634
|
$360,634
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQ10) Do microbiota alter the epigenetic landscape in human genome
|
1R21CA208464-01
|
$254,475
|
$254,475
|
STRONGIN, ALEX
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
1R21CA205644-01
|
$167,475
|
$167,475
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
1R01CA208644-01
|
$377,438
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
|
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS
|
1R21CA206309-01
|
$219,289
|
$219,289
|
HARRIS, REUBEN
|
UNIVERSITY OF MINNESOTA
|
|
|
(PQ3) AGEs and Race Specific Tumor Immune Response in Prostate Cancer
|
5R21CA194469-02
|
$140,445
|
$140,445
|
TURNER, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
1R01CA206476-01
|
$772,521
|
$772,521
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
1R01CA206010-01
|
$369,639
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN
|
|
|
(PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach
|
1R21CA208529-01
|
$198,578
|
$198,578
|
MODIANO, JAIME
|
UNIVERSITY OF MINNESOTA
|
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
1R01CA208756-01
|
$518,165
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
1R01CA206477-01
|
$787,905
|
$787,905
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
(PQ4) Elucidating Determinants of Susceptibility to Tumorigenesis in the Skin
|
1R21CA208298-01
|
$217,016
|
$217,016
|
RAMSEY, MATTHEW
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
(PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas
|
1R21CA208463-01
|
$208,800
|
$208,800
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer
|
1R01CA206465-01
|
$563,374
|
$563,374
|
JUSTICE, AMY
|
YALE UNIVERSITY
|
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
3R01CA194461-02S1
|
$53,843
|
$53,843
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
5R01CA194461-02
|
$340,050
|
$340,050
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
|
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
|
1R01CA208642-01
|
$352,275
|
$352,275
|
SHACKELFORD, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
1R01CA205967-01
|
$390,540
|
$390,540
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
|
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
|
1R01CA206012-01
|
$417,457
|
$417,457
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
1R01CA205975-01A1
|
$386,619
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis
|
1R21CA206352-01
|
$237,750
|
$237,750
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
1R01CA206005-01
|
$351,209
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
1R01CA205632-01
|
$469,489
|
$469,489
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
1R01CA205431-01
|
$533,945
|
$533,945
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
1R01CA205101-01
|
$406,070
|
$406,070
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
|
(PQ8) BONE MARROW-ON-A-CHIP"":AN INVITRO 3D MODEL OF BREAST CANCER DORMANCY
|
1R21CA208519-01
|
$165,844
|
$165,844
|
GEORGE, STEVEN
|
WASHINGTON UNIVERSITY
|
|
|
(PQ9) A novel mechanism of paclitaxel-induced peripheral neuropathy and potential treatment
|
1R01CA208765-01
|
$351,874
|
$351,874
|
YANG, QING
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
1R01CA208634-01
|
$560,277
|
$560,277
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
(PQ9) Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection
|
1R21CA208631-01
|
$251,120
|
$251,120
|
LANNIGAN, DEBORAH
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
1R01CA206028-01
|
$363,112
|
$363,112
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
7R21CA205437-02
|
$152,333
|
$152,333
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.
|
1R21CA205437-01
|
$51,247
|
$51,247
|
WANING, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA)
|
1R21CA208746-01
|
$198,485
|
$198,485
|
KIM, JUNG-WHAN
|
UNIVERSITY OF TEXAS DALLAS
|
|
Total relevant funding to Cancer for this search: $5,206,169,249
|
